Skip to main content
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc — Investor Relations & Filings

Ticker · MGTX ISIN · KYG596651029 LEI · 54930007YV6NYIOGFZ57 US Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-05-14 Major Shareholding Noti…
Country KY Cayman Islands
Listing US MGTX

About MeiraGTx Holdings plc

https://meiragtx.com/

MeiraGTx Holdings plc is a clinical-stage genetic medicine company developing therapies for both rare and prevalent diseases. The company's primary focus areas include disorders of the eye, salivary gland, and central nervous system. MeiraGTx utilizes a proprietary riboswitch gene regulation platform designed to provide precise spatial and temporal control of gene expression. As a vertically integrated entity, it possesses end-to-end capabilities, including its own cGMP manufacturing facilities, to support a broad pipeline of therapeutic candidates. The company has multiple programs in clinical development, with several in late-stage trials.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-05-14 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 13, 2025, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2025. The text states that the full press release is furnished as an exhibit and incorporated by reference, indicating this document itself is a current report filing rather than the earnings release itself. The document length is 3864 characters, which is relatively short and consistent with a regulatory filing notice rather than a full earnings release. The document does not contain substantive financial data or detailed financial statements but references the press release. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report filing referencing an earnings release but not the earnings release itself.
2025-05-13 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about FDA granting RMAT designation to a treatment, which is furnished as an exhibit. The document does not contain financial statements or detailed financial data but rather an announcement of a significant event. The length is under 5,000 characters and it primarily serves as a regulatory announcement. According to the rules, such filings that do not fit other categories and are announcements of events are best classified as Regulatory Filings (RNS).
2025-05-09 English
ARS
Annual Report
2025-04-30 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement related to shareholder voting for an Annual General Meeting (AGM). It includes information about voting items such as election of directors and appointment of auditors, and instructions on how to vote. The document is titled 'Proxy Statement' and is described as 'Definitive Additional Materials' for the AGM. It does not contain the full annual report or financial statements but rather materials to inform shareholders for voting purposes. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is 3430 characters, which is consistent with a proxy statement or voting materials rather than a full report.
2025-04-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.